Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 23;11:438. doi: 10.1038/s41467-020-14332-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a Timeline of experimental procedure. b–d Tumor pictures on day 20 (b), tumor size (c), and survival rate (d) of B16F10 tumor-bearing mice receiving indicated treatments (PBS, n = 9; PIO, n = 9; αGC, n = 10; αGC + PIO, n = 8). Bar, 1 cm. e, f Percentages of NK and CD8⁺ T cells (e; PBS, n = 6; PIO, n = 6; αGC, n = 16; αGC + PIO, n = 12), and percentages of IFN-γ⁺ NK and IFN-γ⁺ CD8⁺ T cells (f; PBS, n = 6; PIO, n = 6; αGC, n = 16; αGC + PIO, n = 10) in tumors from PIO-treated and PIO-untreated mice after injecting with or without 2 μg αGC for 5 h. g Size of tumors from Jα18^−/− mice receiving indicated treatments (PBS, n = 8; αGC + PIO, n = 7). h, i Percentages of NK and CD8⁺ T cells (h), and percentages of IFN-γ⁺ NK and IFN-γ⁺ CD8⁺ T cells (i) in tumors from Jα18^−/− mice receiving indicated treatments as described in f (n = 5 mice per group). j Size of tumors from Ifng^−/− mice receiving indicated treatments (PBS, n = 11; αGC + PIO, n = 9). k Percentages of NK and CD8⁺ T cells in tumors from Ifng^−/− mice receiving indicated treatments (PBS, n = 10; αGC + PIO, n = 8). l Generation of mixed bone marrow chimeras. m PPARγ expression in iNKT cells from PPARγ^Δ mice or WT mice. n Percentages of intratumoral iNKT cells and percentages of IFN-γ⁺ iNKT cells in tumors from PPARγ^Δ or WT mice receiving PIO daily and 2 μg αGC for 5 h (n = 8 mice per group). p, q Tumor size (p) and survival rate (q) of tumor-bearing PPARγ^Δ (n = 8) or WT (n = 10) mice receiving indicated treatments. Error bars represent SEM. Data were analyzed by two-way ANOVA (c, g, j, p), Mann–Whitney test (e, f, h, i, k, n, o), or log-rank test (d, q). *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file.